[
    {
        "nctNumber": "NCT06022029",
        "briefTitle": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas."
    },
    {
        "nctNumber": "NCT05107674",
        "briefTitle": "A Study of NX-1607 in Adults With Advanced Malignancies"
    },
    {
        "nctNumber": "NCT05888831",
        "briefTitle": "A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors"
    },
    {
        "nctNumber": "NCT05579366",
        "briefTitle": "PRO1184 for Advanced Solid Tumors"
    },
    {
        "nctNumber": "NCT05453825",
        "briefTitle": "A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors"
    },
    {
        "nctNumber": "NCT05848739",
        "briefTitle": "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors"
    },
    {
        "nctNumber": "NCT05852691",
        "briefTitle": "A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer"
    },
    {
        "nctNumber": "NCT05929768",
        "briefTitle": "Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer"
    },
    {
        "nctNumber": "NCT05491226",
        "briefTitle": "Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation"
    },
    {
        "nctNumber": "NCT05318469",
        "briefTitle": "Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer"
    },
    {
        "nctNumber": "NCT03546686",
        "briefTitle": "Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer"
    },
    {
        "nctNumber": "NCT05230186",
        "briefTitle": "A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells."
    },
    {
        "nctNumber": "NCT04225117",
        "briefTitle": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)"
    },
    {
        "nctNumber": "NCT06112379",
        "briefTitle": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer"
    },
    {
        "nctNumber": "NCT06422455",
        "briefTitle": "Access to Genetic Testing in Underserved Patients With Cancer"
    },
    {
        "nctNumber": "NCT05082610",
        "briefTitle": "A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab"
    },
    {
        "nctNumber": "NCT06299163",
        "briefTitle": "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors"
    },
    {
        "nctNumber": "NCT05585034",
        "briefTitle": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors"
    },
    {
        "nctNumber": "NCT04333706",
        "briefTitle": "A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)"
    },
    {
        "nctNumber": "NCT05629585",
        "briefTitle": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)"
    },
    {
        "nctNumber": "NCT05252390",
        "briefTitle": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors"
    },
    {
        "nctNumber": "NCT01042379",
        "briefTitle": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer"
    },
    {
        "nctNumber": "NCT05812807",
        "briefTitle": "Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab"
    },
    {
        "nctNumber": "NCT04895709",
        "briefTitle": "A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors"
    },
    {
        "nctNumber": "NCT03401385",
        "briefTitle": "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)"
    },
    {
        "nctNumber": "NCT03504488",
        "briefTitle": "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)"
    },
    {
        "nctNumber": "NCT05989828",
        "briefTitle": "A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer"
    },
    {
        "nctNumber": "NCT05633654",
        "briefTitle": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)"
    },
    {
        "nctNumber": "NCT06353997",
        "briefTitle": "Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients"
    }
]